Celgene Gets CHMP Positive Opinion for Revlimid/Rituximab Combo in Follicular Lymphoma

Date : 11/15/2019 @ 1:22PM
Source : Dow Jones News
Stock : Celgene Corporation (CELG)
Quote : 108.24  0.0 (0.00%) @ 1:00AM

Celgene Gets CHMP Positive Opinion for Revlimid/Rituximab Combo in Follicular Lymphoma

Historical Stock Chart

6 Months : From Oct 2019 to Apr 2020

Click Here for more Celgene Charts.

By Colin Kellaher


Celgene Corp. (CELG) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Revlimid in combination with rituximab for adults with previously treated follicular lymphoma.

The Summit, N.J., biopharmaceutical company said the combination, if approved by the European Commission, would be the first combination treatment regimen for patients with the blood cancer that doesn't include chemotherapy.

The European Commission, which generally follows the CHMP's recommendations, is expected to make its final decision in about two months, Celgene said.

Celgene in January agreed to be acquired by Bristol-Myers Squibb Co. (BMY) in a $74 billion deal expected to close by the end of the year.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

November 15, 2019 08:07 ET (13:07 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest CELG Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.